摘要
近年来,新的放疗技术(如适形放疗和影像引导的放疗等)的应用减少了非小细胞肺癌患者放疗过程中射线下正常肺组织的暴露,但放射性肺炎和肺纤维化仍是提高肺癌靶区剂量的重要制约因素之一。血浆转化生长因子-β(transforming growth factor be-ta,TGF-β)、白细胞介素-6(interleukin-6,IL-6)等细胞因子与放射性肺损伤的发生关系密切。放疗前血浆TGF-β、IL-6和剂量体积参数V20、V30和MLD是放射性肺损伤发生的重要预测因子。几种药物减轻放射性肺损伤的作用已经在动物实验或临床研究中得到证实,如皮质醇激素、氯磷汀、血管紧张素转换酶抑制剂和角化细胞生长因子等。
In recent years, although newer radiotherapy techniques and technologies, such as CRT and IGRT, may reduce the exposure of normal lung to irradiation in patients with non-small cell lung cancer, radiation pneumonitis and pulmonary fibrosis is still one of the most important dose limiting side effects of radiotherapy for lung cancer. Cytokine such as TGF-β（transforming growth factor beta） and IL-6（interleukin 6） are significantly associated with radiation-induced pulmonary injury. Plasma TGF-β, IL-6 and dose-volumetric parameters V20, V30 and MLD before radiotherapy have been proposed as important predictors of the risk of developing radiation injury. Several medications have shown their ability to reduce radiation-induced pulmonary toxicity in animals and humans, including corticosteroids, amifostine, ACE inhibitors, rHuKGF, etc.
出处
《中华肿瘤防治杂志》
CAS
2007年第18期1437-1439,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
国家自然科学基金面上项目(30670617)
关键词
癌
非小细胞肺
放射疗法
辐射损伤
放射性肺炎
肺纤维化
综述文献
carcinoma, non-small cell lung
radiotherapy
radiation injuries
radiation pneumonitis
pulmonary fibrosis
review literature
作者简介
李洪升，男，山东青州人，硕士，主要从事放射肿瘤学研究工作。Tel：86-531-87984777-82162,E-mail：meddi@sohu．com.
【通讯作者】李宝生，男，山东莱阳人，博士，研究员，博士生导师，主要从事放射肿瘤学研究工作。Tell：86-531-87984777-82161,E-mail：baoshli@yahoo．com.
